DISCERN™ Alzheimer’s Disease Diagnostic Is Projected To Save Nearly $5 Million Over Three Years for Medicare Advantage Plans

An economic analysis found that, for a Medicare Advantage plan with one million beneficiaries, the DISCERN™ Alzheimer's disease (AD) diagnostic test is projected to save approximately $4.75 million over three years. This equates to an approximate $63.11 net savings per test per year for a cohort followed over three years. The economic analysis included only the costs for symptomatic treatments.

DISCERN™ was developed to distinguish AD accurately from other forms of dementia, even in consumers recently diagnosed with dementia and those with mixed dementia. Further reducing the current use of medical imaging, such as magnetic imaging (MRI . . .